Spironolactone — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Heart Failure

• Carvedilol
• Digoxin
• Furosemide
• Lisinopril
• Losartan
• Metoprolol

Also listed for Heart Failure (Symptom Control)

• Metoprolol Succinate

Also listed for Liver Disease

• Lactulose

Other medications in Cardiovascular

• Amiodarone
• Aspirin
• Cilostazol
• Clopidogrel
• Dabigatran
• Enoxaparin
• Nitroglycerin

What Spironolactone is approved for (FDA label)

Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ).

Source: Read the full FDA label on DailyMed. Label effective date: September 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Spironolactone (FDA label)

Tablets: 100 mg are white to off-white, round, biconvex, film-coated tablets debossed with '662' on one side and scored on the other side. Tablets: 100 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 8b76a904-6c99-485a-a05f-13a36c5f720c. SPL document ID: 5b870e25-20fd-e75f-e063-6394a90ae7c5. Label effective date: September 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Spironolactone (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Hyperkalemia [see Warnings and Precautions ( 5.1 )] Hypotension and Worsening Renal Function [see Warnings and Precautions ( 5.2 )] Electrolyte and Metabolic Abnormalities [see Warnings and Precautions ( 5.3 )] Gynecomastia [see Warnings and Precautions ( 5.4 )] Impaired neurological function/ coma in patients with hepatic impairment, cirrhosis and ascites [see Use in Specific Populations ( 8.7 )] The following adverse reactions associated with the use of spironolactone were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure. Digestive: Gastric bleeding, ulceration, gastritis, diarrhea and cramping, nausea, vomiting. Reproductive: Decreased libido, inability to achieve or maintain erection, irregular menses or amenorrhea, postmenopausal bleeding, breast and nipple pain. Hematologic: Leukopenia (including agranulocytosis), thrombocytopenia. Hypersensitivity: Fever, urticaria, maculopapular or erythematous cutaneous eruptions, anaphylactic reactions, vasculitis. Metabolism: Hyperkalemia, electrolyte disturbances [see Warnings and Precautions ( 5.1 , 5.3 )] , hyponatremia, hypovolemia. Musculoskeletal : Leg cramps. Nervous system/psychiatric: Lethargy, mental confusion, ataxia, dizziness, headache, drowsiness. Liver/biliary: A very few cases of mixed cholestatic/hepatocellular toxicity, with one reported fatality, have been reported with spironolactone administration. Renal: Renal dysfunction (including renal failure). Skin: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), alopecia, pruritis. The most common adverse reaction with spironolactone treatment is gynecomastia ( 5.4 , 6 ).

Source: FDA prescribing information (DailyMed). Set ID: 8b76a904-6c99-485a-a05f-13a36c5f720c. SPL document ID: 5b870e25-20fd-e75f-e063-6394a90ae7c5. Label effective date: September 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Spironolactone (FDA label)

Spironolactone tablets are contraindicated in the patients with: Hyperkalemia Addison's disease Concomitant use of eplerenone Spironolactone tablets are contraindicated in patients with ( 4 ): Hyperkalemia Addison's disease Concomitant use of eplerenone

Source: FDA prescribing information (DailyMed). Set ID: 8b76a904-6c99-485a-a05f-13a36c5f720c. SPL document ID: 5b870e25-20fd-e75f-e063-6394a90ae7c5. Label effective date: September 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Spironolactone (FDA label)

Hyperkalemia: Monitor serum potassium within one week of initiation and regularly thereafter ( 5.1 ). Hypotension and Worsening Renal Function: Monitor volume status and renal function periodically ( 5.2 ). Electrolyte and Metabolic Abnormalities: Monitor serum electrolytes, uric acid and blood glucose periodically ( 5.3 ). Gynecomastia: Spironolactone can cause gynecomastia ( 5.4 ). 5.1 Hyperkalemia Spironolactone can cause hyperkalemia. This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . Monitor serum potassium within 1 week of initiation or titration of spironolactone and regularly thereafter. More frequent monitoring may be needed when spironolactone is given with other drugs that cause hyperkalemia or in patients with impaired renal function.

Source: FDA prescribing information (DailyMed). Set ID: 8b76a904-6c99-485a-a05f-13a36c5f720c. SPL document ID: 5b870e25-20fd-e75f-e063-6394a90ae7c5. Label effective date: September 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Spironolactone (FDA label)

Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia ( 5.1 , 7.1 ). Lithium: Increased risk of lithium toxicity ( 7.2 ). NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone ( 7.3 ). Digoxin: Spironolactone can interfere with radioimmunologic assays of digoxin exposure ( 7.4 ). Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use ( 7.5 ). Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone ( 7.6 ). Abiraterone: May increase prostate-specific antigen (PSA) levels ( 7.7 ). Mitotane: Avoid concomitant use of spironolactone and mitotane ( 7.8 ). 7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of spironolactone with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia.

Source: FDA prescribing information (DailyMed). Set ID: 8b76a904-6c99-485a-a05f-13a36c5f720c. SPL document ID: 5b870e25-20fd-e75f-e063-6394a90ae7c5. Label effective date: September 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.